Overview

SentiMag® Intraoperative Comparison in Breast Cancer

Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this pivotal study is to provide prospective evidence that the SentiMag®/SiennaXP® is safe and non-inferior to the current standard of care for lymph node localization in patients with breast cancer as part of a sentinel lymph node biopsy (SLNB) procedure and to summarize measures of product safety and performance.
Phase:
N/A
Details
Lead Sponsor:
Endomagnetics Inc
Collaborator:
Regulatory and Clinical Research Institute Inc
Treatments:
Technetium Tc 99m Sulfur Colloid